Literature DB >> 20347403

Alveolar inflammation in cystic fibrosis.

Martina Ulrich1, Dieter Worlitzsch, Simona Viglio, Nanna Siegmann, Paolo Iadarola, Janis K Shute, Marianne Geiser, Gerald B Pier, Godehard Friedel, Mark L Barr, Antje Schuster, Keith C Meyer, Felix Ratjen, Thomas Bjarnsholt, Erich Gulbins, Gerd Döring.   

Abstract

BACKGROUND: In infected lungs of the cystic fibrosis (CF) patients, opportunistic pathogens and mutated cystic fibrosis transmembrane conductance regulator protein (CFTR) contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release and ceramide accumulation. We sought to investigate CF lung inflammation in the alveoli.
METHODS: Lung tissue from 14 CF patients and four healthy individuals was analyzed for numbers of effector cells, elastin and collagen concentrations, inflammatory markers and density of Pseudomonas aeruginosa. Additionally, desmosine and isodesmosine concentrations were determined in 52 urine specimens from CF patients to estimate the burden of elastase activities in respiratory secretions.
RESULTS: Elastin concentration was significantly decreased and collagen significantly increased in CF alveolar tissues as compared to age-matched, healthy individuals. Elastin split products were significantly increased in urine samples from patients with CF and correlated inversely with age, indicating local tissue remodelling due to elastin degradation by unopposed proteolytic enzymes. Alveolar inflammation was also characterized by a significant cell infiltration of neutrophils, macrophages and T cells, extensive nuclear factor-kappaB and insulin-like growth factor-1 activation in various cell types and increased intercellular adhesion molecule-1 expression, and increased numbers of myofibroblasts. Additionally, ceramide accumulated in type II alveolar epithelial cells, lacking CFTR. P. aeruginosa organisms were rarely present in inflamed alveoli.
CONCLUSIONS: Chronic inflammation and remodeling is present in alveolar tissues of the CF lung and needs to be addressed by anti-inflammatory therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347403      PMCID: PMC2883667          DOI: 10.1016/j.jcf.2010.03.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  55 in total

1.  Functional ion channels in pulmonary alveolar type I cells support a role for type I cells in lung ion transport.

Authors:  Meshell D Johnson; Hui-Fang Bao; My N Helms; Xi-Juan Chen; Zac Tigue; Lucky Jain; Leland G Dobbs; Douglas C Eaton
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

2.  Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.

Authors:  M Rosenfeld; R L Gibson; S McNamara; J Emerson; J L Burns; R Castile; P Hiatt; K McCoy; C B Wilson; A Inglis; A Smith; T R Martin; B W Ramsey
Journal:  Pediatr Pulmonol       Date:  2001-11

3.  Aerosol alpha 1-antitrypsin treatment for cystic fibrosis.

Authors:  N G McElvaney; R C Hubbard; P Birrer; M S Chernick; D B Caplan; M M Frank; R G Crystal
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs.

Authors:  H A Tiddens; L P Koopman; R K Lambert; W M Elliott; W C Hop; T W van der Mark; W J de Boer; J C de Jongste
Journal:  Eur Respir J       Date:  2000-04       Impact factor: 16.671

6.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

7.  Elastin and collagen degradation products in urine of patients with cystic fibrosis.

Authors:  P J Stone; M W Konstan; M Berger; H L Dorkin; C Franzblau; G L Snider
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

8.  Quantitative aspects of lung pathology in cystic fibrosis.

Authors:  R E Sobonya; L M Taussig
Journal:  Am Rev Respir Dis       Date:  1986-08

Review 9.  New concepts of the pathogenesis of cystic fibrosis lung disease.

Authors:  R C Boucher
Journal:  Eur Respir J       Date:  2004-01       Impact factor: 16.671

10.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

View more
  45 in total

1.  Role of CD95 in pulmonary inflammation and infection in cystic fibrosis.

Authors:  Katrin Anne Becker; Brian Henry; Regan Ziobro; Burkhard Tümmler; Erich Gulbins; Heike Grassmé
Journal:  J Mol Med (Berl)       Date:  2012-09       Impact factor: 4.599

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  A Flow Cytometric Method for Isolating Cystic Fibrosis Airway Macrophages from Expectorated Sputum.

Authors:  Katherine B Hisert; W Conrad Liles; Anne M Manicone
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

4.  Modulating the alveolar milieu to enhance resolution of fibrotic lung injury.

Authors:  Orquidea Garcia; Sue Buckley; Sonia Navarro; Barbara Driscoll; David Warburton
Journal:  Proc Am Thorac Soc       Date:  2012-07

5.  Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair.

Authors:  Yutaka Itokazu; Richard E Pagano; Andreas S Schroeder; Scott M O'Grady; Andrew H Limper; David L Marks
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-05       Impact factor: 4.249

6.  Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.

Authors:  Sarah A Ingersoll; Julie Laval; Osric A Forrest; Marcela Preininger; Milton R Brown; Dalia Arafat; Greg Gibson; Vin Tangpricha; Rabindra Tirouvanziam
Journal:  J Immunol       Date:  2015-04-29       Impact factor: 5.422

Review 7.  Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective.

Authors:  Anders Folkesson; Lars Jelsbak; Lei Yang; Helle Krogh Johansen; Oana Ciofu; Niels Høiby; Søren Molin
Journal:  Nat Rev Microbiol       Date:  2012-11-13       Impact factor: 60.633

8.  Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids.

Authors:  Anna Caretti; Michele Vasso; Fabiola Tecla Bonezzi; Andrea Gallina; Marco Trinchera; Alice Rossi; Raffaella Adami; Josefina Casas; Monica Falleni; Delfina Tosi; Alessandra Bragonzi; Riccardo Ghidoni; Cecilia Gelfi; Paola Signorelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-24       Impact factor: 3.000

9.  Ceramide mediates lung fibrosis in cystic fibrosis.

Authors:  Regan Ziobro; Brian Henry; Michael J Edwards; Alex B Lentsch; Erich Gulbins
Journal:  Biochem Biophys Res Commun       Date:  2013-03-21       Impact factor: 3.575

10.  Quantitative imaging of airway liquid absorption in cystic fibrosis.

Authors:  Landon W Locke; Michael M Myerburg; Matthew R Markovetz; Robert S Parker; Lawrence Weber; Michael R Czachowski; Thomas J Harding; Stefanie L Brown; Joseph A Nero; Joseph M Pilewski; Timothy E Corcoran
Journal:  Eur Respir J       Date:  2014-04-17       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.